Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma

Basit Öğe Kaydı
dc.authorid0000-0003-3465-1808en_US
dc.authorscopusid57198446979en_US
dc.authorwosidS-9157-2017en_US
dc.contributor.authorAtaş, Merve Nur
dc.contributor.authorErtuğrul, Barış
dc.contributor.authorİplik, Elif Sinem
dc.contributor.authorÇakmakoğlu, Bedia
dc.contributor.authorErgen, Arzu
dc.date.accessioned2022-01-24T11:34:56Z
dc.date.available2022-01-24T11:34:56Z
dc.date.issued2022en_US
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalıen_US
dc.description.abstractObjective: Renal cancer is the most lethal among urological cancer. Treatments of renal cell carcinoma (RCC) may be possible by immune checkpoint inhibitors and drug treatment targeting different molecules. We aimed to determine the apoptotic effect of betulinic acid and its effects on expressions of apoptosisassociated genes AKT-1 and mTOR in RCC cells. Material and methods: In this study, we investigated the apoptotic activity of betulinic acid in CAKI-2 cell line and its effect on AKT-1 and mTOR gene expression levels. In order to do so, following analyses were conducted: WST-1 to identify the toxic effect of betulinic acid, Caspase-3/BCA to detect caspase enzyme activity, Annexin-V and ELISA to determine for apoptotic effect, and finally, real-time PCR for expression levels of AKT-1 and mTOR. Results: Our study showed that different concentrations of betulinic acid induced apoptosis in renal cancer; however, no effect was observed in healthy cells. In gene expression analysis, there was statistically significant decrease in AKT-1 expression level while increasing mTOR expression level. Conclusion: We suggested that betulinic acid with its apoptotic effect on RCC line and nontoxic effect on healthy cell line and the effects on AKT/mTOR pathway may be a potential anticancer drug promising for future studies.en_US
dc.identifier.citationAtaş, M.N., Ertuğrul, B., İplik, E.S., Çakmakoğlu, B., Ergen, A. (2022). Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology. 48(1), pp. 66-71. https://10.5152/tud.2022.21276en_US
dc.identifier.doi10.5152/tud.2022.21276en_US
dc.identifier.endpage71en_US
dc.identifier.issue1en_US
dc.identifier.pmidPMID: 35118990en_US
dc.identifier.scopus2-s2.0-85124884171en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage66en_US
dc.identifier.urihttps://10.5152/tud.2022.21276
dc.identifier.urihttps://hdl.handle.net/20.500.13055/147
dc.identifier.volume48en_US
dc.identifier.wosWOS:000744571800016en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherESCI - Emerging Sources Citation Indexen_US
dc.institutionauthorİplik, Elif Sinem
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTurkish Journal of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApoptosisen_US
dc.subjectBetulinic Aciden_US
dc.subjectExpressionen_US
dc.subjectPathwayen_US
dc.subjectRenal Canceren_US
dc.titleEffects of betulinic acid on AKT/mTOR pathway in renal cell carcinomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
08_SA-AVES-TJU#210045 (1).pdf
Boyut:
507.62 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu